A data breach at drug distributor Cencora has left sensitive information vulnerable, with patients on medicines from a dozen ...

Bolstered by a full FDA approval for its primary immunoglobulin A nephropathy (IgAN) treatment Tarpeyo, Calliditas has earned ...

A recently announced $900 million restructuring drive is already making waves at Takeda, wi | From early July to March 2025, ...

Novartis is eyeing an FDA filing for a second drug in immunoglobulin A nephropathy (IgAN), as the Swiss pharma goes all-in on ...

Since NS Pharma launched its Duchenne muscular dystrophy (DMD) drug Viltepso (viltolarsen) in 2020, sales have steadily ...

The FDA, which issued India’s Laurus Synthesis a Form 483 in January, followed up the action with an "untitled letter" (PDF) ...

JPA Health’s growth spurt continues, as the marketing and PR agency has made its second acquisition in less than a year. | ...

Merck KGaA’s North American life science division, MilliporeSigma, has made U.S. | The U.S. Department of Justice on ...

While it’s hard to overstate the success Novo Nordisk’s GLP-1 franchise has already achieved, the company’s latest deep dive ...

Ahead of the FDA’s decision on Bristol Myers Squibb’s schizophrenia treatment KarXT, the Big Pharma has kicked off a campaign ...

That’s according to a new survey and report from IQVIA, timed to come out alongside this year’s American Society of Clinical ...

Since scoring approval two years ago for its next-generation diabetes treatment Mounjaro (tirzepatide), Eli Lilly has been ...